Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Inotiv, Inc.
  6. News
  7. Summary
    NOTV   US45783Q1004


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inotiv : Acquires Laboratory Instrumentation for Discovery and Development of Novel Therapies

07/15/2021 | 08:33am EDT

WEST LAFAYETTE, Ind., July 15, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and bioanalytical drug discovery and development services, today announced that the Company has purchased the physical assets of a Tennessee-based laboratory services provider that ceased operations. The assets, which include lab instrumentation, stock consumables and chemicals, lab benchwork, and office furniture, were acquired for approximately $1.3 million, a substantial discount to the Company’s estimate of fair market value.

The acquired assets will accelerate the Company’s expansion of its regulated (GLP/GCLP) laboratory services and solutions for biopharmaceutical companies pursuing cell and gene therapy (CGT) as well as traditional biotherapeutics and immunotherapies.

Kenneth Swart, Ph.D., Vice President, Bioanalytical Sciences commented, “The state-of-the-art cell and molecular biology instrumentation we acquired will significantly accelerate the completion of a new regulated laboratory operation that we plan to build in support of our broadening biotherapeutics client base. We currently are exploring locations for the operation as well as building the scientific and business team that will execute on Inotiv’s expanded biotherapeutics initiative.”

This investment in laboratory assets coincides with recent announcements of expanded drug discovery laboratory and in-life services at Inotiv’s St. Louis-based operation and recently acquired Boulder, CO, sites (formerly Bolder BioPATH, Inc. and HistoTox Labs, Inc.), the footprints of which effectively extended the Company’s breadth of DMPK, cell & molecular biology and pharmacology offerings for clients pursuing traditional small molecule therapies and novel cell and gene therapies.

“This opportunistic purchase of laboratory instrumentation and supporting equipment represents not only a key step towards our further expansion into biotherapeutics drug development, but also signals our commitment to establishing Inotiv as a comprehensive partnered research organization to our broad and expanding biopharmaceutical client base,” said Greg Beattie, Chief Operating Officer at Inotiv. “We are committed to creating a distinct presence in the market supporting companies developing novel cell and gene therapies.”

About the Company
Inotiv, Inc. is a leading contract research organization specializing in nonclinical and analytical drug discovery and development services. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.

Company Contact Investor Relations
Inotiv, Inc. The Equity Group Inc.
Beth A. Taylor, Chief Financial Officer Kalle Ahl, CFA
(765) 497-8381 (212) 836-9614
btaylor@inotivco.com kahl@equityny.com
  Devin Sullivan
  (212) 836-9608

Primary Logo

Source: Inotiv, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about INOTIV, INC.
09/14INOTIV, INC. : Change in Directors or Principal Officers (form 8-K)
09/14Inotiv, Inc. Terminates Employment of Joseph E. Flynn as Chief Commercial Off..
08/31INOTIV : to Participate in the 2021 Colliers Institutional Investor Conference
08/18INOTIV : 3rd Qtr 10Q
08/11INOTIV : Announces Third Quarter Fiscal 2021 Financial Results (Form 8-K)
08/11INOTIV, INC. : Results of Operations and Financial Condition, Financial Statemen..
08/11INOTIV : Earnings Flash (NOTV) INOTIV Reports Q3 Revenue $22.9M, vs. Street Est ..
08/11INOTIV : Announces Third Quarter Fiscal 2021 Financial Results
08/10INOTIV : Financial Statements and Exhibits (form 8-K/A)
More news
Analyst Recommendations on INOTIV, INC.
More recommendations
Financials (USD)
Sales 2021 84,0 M - -
Net income 2021 -5,15 M - -
Net Debt 2021 - - -
P/E ratio 2021 -87,8x
Yield 2021 -
Capitalization 558 M 558 M -
Capi. / Sales 2021 6,65x
Capi. / Sales 2022 4,31x
Nbr of Employees 409
Free-Float 62,5%
Duration : Period :
Inotiv, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOTIV, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 32,50 $
Average target price 38,00 $
Spread / Average Target 16,9%
EPS Revisions
Managers and Directors
Robert Leasure President, Chief Executive Officer & Director
Beth A. Taylor Chief Financial Officer, Secretary & VP-Finance
Gregory C. Davis Chairman
John Gregory Beattie Chief Operating Officer
Richard Allen Johnson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INOTIV, INC.0.00%517
MODERNA, INC.321.80%177 867
LONZA GROUP AG36.36%62 278
CELLTRION, INC.-23.26%31 021
SEAGEN INC.-12.32%27 940